These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23492364)

  • 41. Molecular mechanisms of OLIG2 transcription factor in brain cancer.
    Tsigelny IF; Kouznetsova VL; Lian N; Kesari S
    Oncotarget; 2016 Aug; 7(33):53074-53101. PubMed ID: 27447975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma.
    Olmez I; Zhang Y; Manigat L; Benamar M; Brenneman B; Nakano I; Godlewski J; Bronisz A; Lee J; Abbas T; Abounader R; Purow B
    Cancer Res; 2018 Aug; 78(15):4360-4369. PubMed ID: 29844123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors.
    Guichet PO; Bieche I; Teigell M; Serguera C; Rothhut B; Rigau V; Scamps F; Ripoll C; Vacher S; Taviaux S; Chevassus H; Duffau H; Mallet J; Susini A; Joubert D; Bauchet L; Hugnot JP
    Glia; 2013 Feb; 61(2):225-39. PubMed ID: 23047160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
    Bao XH; Takaoka M; Hao HF; Fukazawa T; Yamatsuji T; Sakurama K; Takigawa N; Nakajima M; Fujiwara T; Naomoto Y
    Oncol Rep; 2013 Jan; 29(1):45-50. PubMed ID: 23064324
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.
    Lu F; Chen Y; Zhao C; Wang H; He D; Xu L; Wang J; He X; Deng Y; Lu EE; Liu X; Verma R; Bu H; Drissi R; Fouladi M; Stemmer-Rachamimov AO; Burns D; Xin M; Rubin JB; Bahassi EM; Canoll P; Holland EC; Lu QR
    Cancer Cell; 2016 May; 29(5):669-683. PubMed ID: 27165742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.
    Talukdar S; Das SK; Pradhan AK; Emdad L; Shen XN; Windle JJ; Sarkar D; Fisher PB
    Oncotarget; 2016 Aug; 7(34):54102-54119. PubMed ID: 27472461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selective calcium sensitivity in immature glioma cancer stem cells.
    Wee S; Niklasson M; Marinescu VD; Segerman A; Schmidt L; Hermansson A; Dirks P; Forsberg-Nilsson K; Westermark B; Uhrbom L; Linnarsson S; Nelander S; Andäng M
    PLoS One; 2014; 9(12):e115698. PubMed ID: 25531110
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.
    Zaidi S; McLaughlin M; Bhide SA; Eccles SA; Workman P; Nutting CM; Huddart RA; Harrington KJ
    PLoS One; 2012; 7(4):e35436. PubMed ID: 22523597
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma.
    Ligon KL; Huillard E; Mehta S; Kesari S; Liu H; Alberta JA; Bachoo RM; Kane M; Louis DN; Depinho RA; Anderson DJ; Stiles CD; Rowitch DH
    Neuron; 2007 Feb; 53(4):503-17. PubMed ID: 17296553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
    Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
    J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. β-escin selectively targets the glioblastoma-initiating cell population and reduces cell viability.
    Harford-Wright E; Bidère N; Gavard J
    Oncotarget; 2016 Oct; 7(41):66865-66879. PubMed ID: 27589691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.
    Brown DV; Filiz G; Daniel PM; Hollande F; Dworkin S; Amiridis S; Kountouri N; Ng W; Morokoff AP; Mantamadiotis T
    PLoS One; 2017; 12(2):e0172791. PubMed ID: 28241049
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel function of OLIG2 to suppress human glial tumor cell growth via p27Kip1 transactivation.
    Tabu K; Ohnishi A; Sunden Y; Suzuki T; Tsuda M; Tanaka S; Sakai T; Nagashima K; Sawa H
    J Cell Sci; 2006 Apr; 119(Pt 7):1433-41. PubMed ID: 16554441
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
    Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
    Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
    Niibori-Nambu A; Midorikawa U; Mizuguchi S; Hide T; Nagai M; Komohara Y; Nagayama M; Hirayama M; Kobayashi D; Tsubota N; Takezaki T; Makino K; Nakamura H; Takeya M; Kuratsu J; Araki N
    PLoS One; 2013; 8(5):e59558. PubMed ID: 23704872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.
    Fròsina G; Profumo A; Marubbi D; Marcello D; Ravetti JL; Daga A
    Radiat Oncol; 2018 Apr; 13(1):76. PubMed ID: 29685176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyclin D1 is required for proliferation of Olig2-expressing progenitor cells in the injured cerebral cortex.
    Nobs L; Nestel S; Kulik A; Nitsch C; Atanasoski S
    Glia; 2013 Sep; 61(9):1443-55. PubMed ID: 23839966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.